{{Rsnum
|rsid=7142881
|Gene=NUBPL
|Chromosome=14
|position=31624342
|Orientation=plus
|GMAF=0.4789
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=NUBPL
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 32.7 | 46.9 | 20.4
| HCB | 28.1 | 51.1 | 20.7
| JPT | 32.1 | 50.9 | 17.0
| YRI | 1.4 | 23.1 | 75.5
| ASW | 7.0 | 33.3 | 59.6
| CHB | 28.1 | 51.1 | 20.7
| CHD | 43.5 | 42.6 | 13.9
| GIH | 26.7 | 45.5 | 27.7
| LWK | 4.6 | 31.5 | 63.9
| MEX | 36.8 | 45.6 | 17.5
| MKK | 9.7 | 49.0 | 41.3
| TSI | 31.4 | 48.0 | 20.6
| HapMapRevision=28
}}

{{GWAS Summary
|SNP=rs7142881
|PubMedID=18521091
|Condition=Response to iloperidone treatment (QT prolongation)
|Gene=NUBPL
|Risk Allele=A
|pValue=2.00E-006
|OR=NA
|95CI=
}}

{{PharmGKB
|RSID=rs7142881
|Name_s=
|Gene_s=NUBPL
|Feature=
|Evidence=PubMed ID:18521091; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia (Initial Sample Size: 183 individuals; Replication Sample Size: NR; Risk Allele: rs7142881-A). This variant is associated with Response to iloperidone treatment (QT prolongation).
|Drugs=iloperidone
|Drug Classes=
|Diseases=Acquired Long QT Syndrome (aLQTS); congenital long QT syndrome; Long QT Syndrome
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356591
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7142881
|overall_frequency_n=53
|overall_frequency_d=128
|overall_frequency=0.414062
|n_genomes=34
|n_genomes_annotated=0
|n_haplomes=44
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}